Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lonafarnib
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Eiger BioPharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Zokinvy® (lonafarnib), is a first-in-class disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins which leads to cellular instability and premature aging in children and young adults with progeria.
Brand Name : Zokinvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2022
Lead Product(s) : Lonafarnib
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Eiger BioPharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
